InvestorsObserver
×
News Home

How Will the Market React to Affimed NV (AFMD) Stock Getting a Bullish Rating

Monday, May 22, 2023 11:59 AM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to Affimed NV (AFMD) Stock Getting a Bullish Rating

The market has been high on Affimed NV (AFMD) stock recently. AFMD gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Affimed NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AFMD!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AFMD Stock Today?

Affimed NV (AFMD) stock has fallen -1.85% while the S&P 500 has gained 0.05% as of 11:59 AM on Monday, May 22. AFMD is lower by -$0.02 from the previous closing price of $1.08 on volume of 394,352 shares. Over the past year the S&P 500 has gained 5.55% while AFMD is lower by -67.58%. AFMD lost -$0.65 per share in the over the last 12 months. To screen for more stocks like Affimed NV click here.

More About Affimed NV

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. Click Here to get the full Stock Report for Affimed NV stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App